B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.